London Stock Exchange Welcomes Verici Dx plc to AIM


London Stock Exchange welcomes Verici Dx plc (‘Verici Dx’ or the ‘Company’), a developer of advanced clinical diagnostics for organ transplant, to celebrate the listing of the Company's public shares onto AIM, under the ticker "VRCI".

Verici Dx is an immuno-diagnostics development company, initially focused on the kidney transplantation market. The Company's kidney transplant assays will use advanced next-generation sequencing that may define a personalised risk profile of each patient over the course of their transplant journey and may also detect injury in advance of currently available clinical tests.

The Company develops tests to understand how a patient is likely to, and may be, responding to kidney transplant. There are two leading products for clinical validation and commercialisation:

•    Clarava™, which is a pre-transplant prognosis for the risk of early acute rejection; and
•    Tuteva™, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatinine levels.

Verici Dx raised £14.5m gross significantly oversubscribed fundraising with net proceeds being used to undertake clinical utility and validation studies, to bioinformatics and health economic studies as well as staff and related benefits, for general corporate overheads and for license and royalties and capital expenditure (including to build additional testing capacity).

Sara Barrington, CEO of Verici Dx, said: “We are very grateful for the strong support shown by institutional and other investors to the Verici Dx IPO.  Obtaining funding in a public market is a strong signal of quality to prospective partners and customers, raises the profile of the business and its innovative products considerably, and gives us a supportive platform as we advance our strategy.  We look forward to providing further updates on the execution of our validation and commercialisation plans as we deploy the capital raised towards addressing a significant unmet clinical need.”

To find out more about Verici Dx visit:  www.vericidx.com

Quick facts

Track
Market: AIM
Instrument market cap (£m)
104.89
Listing/Admission to trading
03 Nov 2020
Looking for new and recent issues?

More recent

33.32
London Stock Exchange welcomes HydrogenOne Capital Growth plc to the Premium Segment of the Main Market

HydrogenOne Capital Growth plc, the first London listed hydrogen fund, offers growth potential in clean hydrogen and related technologies. The Company offers investors diversified exposure to private equity and listed hydrogen companies on an international basis. The Company has today listed on the premium segment of London Stock Exchange's main market and qualifies for the Green Economy Mark.<

Learn more
London Stock Exchange welcomes Seplat Energy’s Capital Markets Day

Seplat Energy has today opened London Stock Exchange trading at an official Market Opening ceremony. 

Seplat Energy is a leading independent energy company operating in the prolific Niger Delta area of Nigeria and a leading supplier of processed gas to the domestic market. In 2014 the company completed the first ever dual listing on both the London Stock Exchange (LSEG) and

Learn more
London Stock Exchange welcomes Spinnaker Acquisitions Plc to the Main Market

Spinnaker Acquisitions Plc (“SPAQ”) is a newly established purpose-built cash shell aiming to support businesses and projects in the areas of Sustainability and Energy Transition. With interest in the green economy as keen as it is currently, the objective is to find a business valued at £5–30M with strong profit potential and likely market appetite. 

SPAQ is a company co-founded

Learn more
London Stock Exchange welcomes BIG TECHNOLOGIES PLC to AIM

Big Technologies PLC, the UK-based, remote people monitoring technology company, has today taken the next step in its long-term growth strategy as it is admitted to AIM of London Stock Exchange. It is now trading on AIM, having raised gross proceeds in excess of £200 million, with ticker BIG. At the placing price of 200p per share, Big Technologies PLC has a market capitalisation of £577 millio

Learn more